Significance of Molecular Markers in Survival Prediction of Oral Squamous Cell Carcinoma
Overview
Affiliations
Background: An accurate system for predicting the survival of patients with oral squamous cell carcinoma (OSCC) will be useful for deciding appropriate therapies. The prediction accuracy of prediction models can be improved by using molecular biomarkers. We constructed a nomogram for predicting the survival of patients with OSCC using clinical variables and molecular markers.
Methods: Protein 53 (p53), insulin-like growth factor II mRNA-binding protein 3 (IMP3), cyclooxygenase 2 (COX2), and HuR were localized immunohistochemistry in 96 patients with primary OSCC who underwent surgical resection between January 1994 and June 2003 at the Yonsei Dental Hospital in Seoul, Korea.
Results: On univariate and multivariate analysis, the expression of IMP3 was significantly associated with the risk of death. P53 was also significantly associated with survival of OSCC in the case of negative IMP3 and the prediction accuracy was improved by including these 2 factors in the prediction model.
Conclusion: Survival in OSCC can be predicted more accurately by using biomarkers. The constructed nomogram predicted survival after treatment for an individual patient with OSCC, and it can be practically used as a tool to help decide which adjuvant treatment is most appropriate.
Inflammation as a driver of hematological malignancies.
Saluja S, Bansal I, Bhardwaj R, Beg M, Palanichamy J Front Oncol. 2024; 14:1347402.
PMID: 38571491 PMC: 10987768. DOI: 10.3389/fonc.2024.1347402.
Biasin F, Franco A, Louzeiro G, Cherubini K, Salum F Asian Pac J Cancer Prev. 2024; 25(3):757-766.
PMID: 38546058 PMC: 11152409. DOI: 10.31557/APJCP.2024.25.3.757.
Role of IGF2BPs in head and neck squamous cell carcinoma.
Wu K, Chang F, Li W, Su T, Lei D Front Oncol. 2022; 12:1003808.
PMID: 36237306 PMC: 9552850. DOI: 10.3389/fonc.2022.1003808.
HuR as a molecular target for cancer therapeutics and immune-related disorders.
Majumder M, Chakraborty P, Mohan S, Mehrotra S, Palanisamy V Adv Drug Deliv Rev. 2022; 188:114442.
PMID: 35817212 PMC: 10276344. DOI: 10.1016/j.addr.2022.114442.
Sundaram G, Quah S, Guang L, Sampath P Am J Cancer Res. 2021; 11(10):4981-4993.
PMID: 34765305 PMC: 8569354.